Clinical Trial Update: Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of the XTD regimen (Selinexor, Thalidomide, and Dexamethasone) in adults with relapsed/refractory Lang…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Thalidomide (thalidomide)
• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Langerhans Cell Histiocytosis (LCH) | Phase 2 | Status: ACTIVE_NOT_RECRUITING